Back to search

BIOTEK2021-Bioteknologi for verdiskaping

KOMM: PRESORT-Platform for clinical decision support for precision therapy

Alternative title: PRESORT: Platform for klinisk beslutningsstøtte for presisjonsmedisin

Awarded: NOK 8.0 mill.

In the PRESORT project we aim to predict anti cancer drug responses and understand why some drugs act better when applied together compared to other drug combinations, with the aim of tailoring treatment for each patient. We combine theoretical understanding of molecular cancer biology with experiments where we test drugs on patient-derived tissue samples. Testing medication on patient-derived cancer cells We test drugs on patient-derived cancer biopsies, termed spheroids. Tissue samples are taken directly from the operating theatre at St Olavs university hospital to the integrated laboratory at NTNU, where we culture the cancer cells as small lumps of tissue (spheroids) in a controlled environment. These cultures are next studied in large-scale drug-testing which we perform in collaboration with SINTEF?s drug-screening laboratory. Data-simulation of cancer disease We simulate cancer disease in computer models calibrated to each patient. This provides a low risk and low cost solution to simulate the effect of an array of treatments. The most promising treatments are then tested on patient-derived samples, in order to functionally valdidate and identify potential therapies for the patient. The ambition of the PRESORT project is to provide a functional precision medicine pipeline for clinical decision support, by underpinning choice of cancer treatment by combined computer-simulation and testing on the patient?s cancer cells. Furthermore, we seek to apply our computional and experimental pipeline to accelerate new drug target combination discovery, thereby underpinning pharmaceutical drug screen discovery pipelines. We have by 2021 included three dozens of samples and have a high successrate in cancer cell growth.

Funding scheme:

BIOTEK2021-Bioteknologi for verdiskaping